Why Is Archer Aviation Stock Going Up?
Archer Aviation (NYSE:ACHR) is an aviation startup that is working…
Buy
63
LIXT Quote, Financials, Valuation and Earnings
Last price:
$4.04
Seasonality move
:
-1.61%
Day range:
$3.70 - $4.35
52-week range:
$0.64 - $4.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
255.8K
Avg. volume:
4.2M
1-year change:
60.47%
Market cap:
$11.2M
Revenue:
--
EPS (TTM):
-$1.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings
|
-- | -- | -- | -- | -- |
|
CELU
Celularity
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.43 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings
|
$4.06 | -- | $11.2M | -- | $0.00 | 0% | -- |
|
CELU
Celularity
|
$3.03 | -- | $72.6M | -- | $0.00 | 0% | 1.22x |
|
NBY
NovaBay Pharmaceuticals
|
$0.66 | $0.85 | $3.9M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.68 | -- | $27M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.35 | $1.00 | $966.3K | -- | $0.00 | 0% | 0.43x |
|
TOVX
Theriva Biologics
|
$0.48 | $7.00 | $4M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings
|
-- | 0.607 | -- | -- |
|
CELU
Celularity
|
71.15% | 2.144 | 65.26% | 0.12x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings
|
-- | -$706.9K | -- | -- | -- | -$568.5K |
|
CELU
Celularity
|
$5.4M | -$11.5M | -50.77% | -118.79% | -154.32% | -$179K |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Lixte Biotechnology Holdings vs. Competitors
-
Which has Higher Returns LIXT or CELU?
Celularity has a net margin of -- compared to Lixte Biotechnology Holdings's net margin of -173.17%. Lixte Biotechnology Holdings's return on equity of -- beat Celularity's return on equity of -118.79%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings-- -$0.29 -- CELUCelularity58.23% -$0.73 $59.9M -
What do Analysts Say About LIXT or CELU?
Lixte Biotechnology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Celularity has an analysts' consensus of -- which suggests that it could grow by 725.08%. Given that Celularity has higher upside potential than Lixte Biotechnology Holdings, analysts believe Celularity is more attractive than Lixte Biotechnology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings0 0 0 CELUCelularity0 0 0 -
Is LIXT or CELU More Risky?
Lixte Biotechnology Holdings has a beta of 0.309, which suggesting that the stock is 69.105% less volatile than S&P 500. In comparison Celularity has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.733%.
-
Which is a Better Dividend Stock LIXT or CELU?
Lixte Biotechnology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celularity offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings pays -- of its earnings as a dividend. Celularity pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or CELU?
Lixte Biotechnology Holdings quarterly revenues are --, which are smaller than Celularity quarterly revenues of $9.3M. Lixte Biotechnology Holdings's net income of -$709.6K is higher than Celularity's net income of -$16.1M. Notably, Lixte Biotechnology Holdings's price-to-earnings ratio is -- while Celularity's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings is -- versus 1.22x for Celularity. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings-- -- -- -$709.6K CELUCelularity1.22x -- $9.3M -$16.1M
-
Which has Higher Returns LIXT or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Lixte Biotechnology Holdings's net margin of -49.65%. Lixte Biotechnology Holdings's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings-- -$0.29 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About LIXT or NBY?
Lixte Biotechnology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 28.21%. Given that NovaBay Pharmaceuticals has higher upside potential than Lixte Biotechnology Holdings, analysts believe NovaBay Pharmaceuticals is more attractive than Lixte Biotechnology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is LIXT or NBY More Risky?
Lixte Biotechnology Holdings has a beta of 0.309, which suggesting that the stock is 69.105% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock LIXT or NBY?
Lixte Biotechnology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or NBY?
Lixte Biotechnology Holdings quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Lixte Biotechnology Holdings's net income of -$709.6K is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Lixte Biotechnology Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings-- -- -- -$709.6K NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns LIXT or NNVC?
Nanoviricides has a net margin of -- compared to Lixte Biotechnology Holdings's net margin of --. Lixte Biotechnology Holdings's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings-- -$0.29 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About LIXT or NNVC?
Lixte Biotechnology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 286.91%. Given that Nanoviricides has higher upside potential than Lixte Biotechnology Holdings, analysts believe Nanoviricides is more attractive than Lixte Biotechnology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings0 0 0 NNVCNanoviricides0 0 0 -
Is LIXT or NNVC More Risky?
Lixte Biotechnology Holdings has a beta of 0.309, which suggesting that the stock is 69.105% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock LIXT or NNVC?
Lixte Biotechnology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or NNVC?
Lixte Biotechnology Holdings quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Lixte Biotechnology Holdings's net income of -$709.6K is higher than Nanoviricides's net income of -$2.2M. Notably, Lixte Biotechnology Holdings's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings-- -- -- -$709.6K NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns LIXT or OGEN?
Oragenics has a net margin of -- compared to Lixte Biotechnology Holdings's net margin of --. Lixte Biotechnology Holdings's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings-- -$0.29 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About LIXT or OGEN?
Lixte Biotechnology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2122.44%. Given that Oragenics has higher upside potential than Lixte Biotechnology Holdings, analysts believe Oragenics is more attractive than Lixte Biotechnology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings0 0 0 OGENOragenics0 1 0 -
Is LIXT or OGEN More Risky?
Lixte Biotechnology Holdings has a beta of 0.309, which suggesting that the stock is 69.105% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock LIXT or OGEN?
Lixte Biotechnology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or OGEN?
Lixte Biotechnology Holdings quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Lixte Biotechnology Holdings's net income of -$709.6K is higher than Oragenics's net income of -$2.2M. Notably, Lixte Biotechnology Holdings's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings is -- versus 0.43x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings-- -- -- -$709.6K OGENOragenics0.43x -- -- -$2.2M
-
Which has Higher Returns LIXT or TOVX?
Theriva Biologics has a net margin of -- compared to Lixte Biotechnology Holdings's net margin of --. Lixte Biotechnology Holdings's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings-- -$0.29 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About LIXT or TOVX?
Lixte Biotechnology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1349.28%. Given that Theriva Biologics has higher upside potential than Lixte Biotechnology Holdings, analysts believe Theriva Biologics is more attractive than Lixte Biotechnology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings0 0 0 TOVXTheriva Biologics1 1 0 -
Is LIXT or TOVX More Risky?
Lixte Biotechnology Holdings has a beta of 0.309, which suggesting that the stock is 69.105% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock LIXT or TOVX?
Lixte Biotechnology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or TOVX?
Lixte Biotechnology Holdings quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Lixte Biotechnology Holdings's net income of -$709.6K is higher than Theriva Biologics's net income of -$4.3M. Notably, Lixte Biotechnology Holdings's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings-- -- -- -$709.6K TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Brown Forman Stock Go?
On the surface, Brown‑Forman (NYSE: BF.B) is having an unremarkable year.…
Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
